Literature DB >> 10952425

Cardiac transplantation: the final therapeutic option for the treatment of heart failure.

M M Koerner1, J B Durand, J A Lafuente, G P Noon, G Torre-Amione.   

Abstract

End-stage heart failure is still associated with a decrease in quality and prognosis of life. Cardiac transplantation remains the final extraordinary therapeutic option for the treatment of truly irreversible end-stage heart failure in all age groups. The selection process of candidates and the acceptance of patients with relative contra-indications is characterized by the experience and skills of an interdisciplinary transplant team, which should have access to different mechanical circulatory support systems for short-term or long-term use: bridging to transplant as well as for recovery.

Entities:  

Mesh:

Year:  2000        PMID: 10952425     DOI: 10.1097/00001573-200005000-00010

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  6 in total

1.  Neutrophil mediated smooth muscle cell loss precedes allograft vasculopathy.

Authors:  Chelsey L King; Jennifer J Devitt; Timothy D G Lee; Camille L Hancock Friesen
Journal:  J Cardiothorac Surg       Date:  2010-06-22       Impact factor: 1.637

2.  Role of Mitogen-Activated Protein Kinases in Myocardial Ischemia-Reperfusion Injury during Heart Transplantation.

Authors:  Giuseppe Vassalli; Giuseppina Milano; Tiziano Moccetti
Journal:  J Transplant       Date:  2012-03-18

3.  Isolation and characterization of a Sca-1+/CD31- progenitor cell lineage derived from mouse heart tissue.

Authors:  Hao Wang; Hao Chen; Bei Feng; Xiang Wang; Xiaomin He; Renjie Hu; Meng Yin; Wei Wang; Wei Fu; Zhiwei Xu
Journal:  BMC Biotechnol       Date:  2014-08-09       Impact factor: 2.563

4.  Effect of everolimus on the immunomodulation of the human neutrophil inflammatory response and activation.

Authors:  Damien Vitiello; Paul-Eduard Neagoe; Martin G Sirois; Michel White
Journal:  Cell Mol Immunol       Date:  2014-06-02       Impact factor: 11.530

5.  Sphingosine 1-Phosphate Receptor Modulator Fingolimod (FTY720) Attenuates Myocardial Fibrosis in Post-heterotopic Heart Transplantation.

Authors:  Naseer Ahmed; Daniele Linardi; Nazeer Muhammad; Cristiano Chiamulera; Guido Fumagalli; Livio San Biagio; Mebratu A Gebrie; Muhammad Aslam; Giovanni Battista Luciani; Giuseppe Faggian; Alessio Rungatscher
Journal:  Front Pharmacol       Date:  2017-09-15       Impact factor: 5.810

6.  Fingolimod (FTY720) Preserves High Energy Phosphates and Improves Cardiac Function in Heterotopic Heart Transplantation Model.

Authors:  Naseer Ahmed; Javeria Farooq; Soban Sadiq; Sultan Ayoub Meo; Azam Jan; Faisal H Cheema; Giuseppe Faggian; Alessio Rungatscher
Journal:  Int J Mol Sci       Date:  2020-09-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.